Teleflex (TFX) Gains FDA Approval for TrapLiner Catheter
Based in Wayne, PA, Teleflex Incorporated TFX, a global provider of medical technologies, recently announced 510(k) clearance for its TrapLiner Catheter from the US FDA for a full fledged commercial launch in the country. Meanwhile we note that TrapLiner has been developed by Vascular Solutions, which was acquired by Teleflex on Feb 17, 2017.
The Trapliner Catheter is a modified version of Vascular Solutions’ flagship GuideLiner Guide Extension Catheter used for angioplasty. Notably, the device can be used as an alternative to the already existing ‘trapping technique’ that requires the use of a percutaneous transluminal coronary angioplasty (PTCA) balloon to replace an existing over-the-wire catheter while maintaining guidewire position.
Stock Performance
Since the announcement, Teleflex witnessed a nominal 0.3% increase in its share price to $184.01 on Feb 22.
The price performance of Teleflex has been robust. Over the last three months, the stock added 21.7%, much higher than the Zacks classified Medical Instrument sub-industry’s gain of 6.8%. Furthermore, the current return of the stock is ahead of the S&P 500’s 6.2% over the same time frame.
On the flip side, the company’s recent earnings estimates have been dismal. The current quarter has seen four estimates move south in the past 60 days compared to no movement in the opposite direction. As a result, the current quarter estimates dropped almost 1% to $2.08.
These mixed sentiments justify the stock’s Zacks Rank #3 (Hold).
Bottom Line
Taking the latest regulatory progress into consideration, the bountiful opportunities in the global angioplasty balloons market buoy optimism. In this regard, an analysis by the Zion Market research projects the niche market to generate revenue worth $2.41 billion by 2021, multiplying at a CAGR of around 4.3%
Of late, Teleflex has been gaining traction in the niche markets, courtesy of a plethora of regulatory approvals. The company received FDA clearances for its Arrow Midline with Chlorag+ard Technology, Arrow JACC and TightTrack tunneler platforms as well.
Teleflex Incorporated Price
Teleflex Incorporated Price | Teleflex Incorporated Quote
The company also recently announced the launch of LMA Gastro Airway with Cuff Pilot Technology. Furthermore, the recent receipt of 510(k) approval from the U.S. FDA for its Arrow VPS Rhythm device for commercial use is a strong positive in our view (read more: Teleflex Launches LMA Gastro Airway, FDA Okays Arrow VPS).
Stocks to Consider
Better-ranked stocks in the broader medical sector include Glaukos Corporation GKOS, Avinger, Inc. AVGR and Fluidigm Corporation FLDM. Notably, Glaukos and Fluidigm sport a Zacks Rank #1 (Strong Buy) while Avinger carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 180.4%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm Corporation has a long-term expected earnings growth rate of 25%. The stock has added 6.08% over the last one year.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? Last year's market-beating Top 10 portfolio produced 5 double-digit winners. For example, oil and natural gas giant Pioneer Natural Resources and First Republic Bank racked up stellar gains of +44.9% and +44.3% respectively. Now a brand-new list for 2017 has been hand-picked from 4,400 companies covered by the Zacks Rank. See the 2017 Top 10 right now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teleflex Incorporated (TFX): Free Stock Analysis Report
Fluidigm Corporation (FLDM): Free Stock Analysis Report
Avinger, Inc. (AVGR): Free Stock Analysis Report
Glaukos Corporation (GKOS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
